Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 1
1952 1
1953 1
1954 3
1955 5
1956 4
1957 6
1958 1
1960 3
1961 6
1962 7
1963 6
1964 10
1965 16
1966 16
1967 12
1968 26
1969 22
1970 17
1971 24
1972 13
1973 7
1974 18
1975 11
1976 28
1977 21
1978 32
1979 36
1980 40
1981 43
1982 40
1983 64
1984 93
1985 106
1986 89
1987 111
1988 117
1989 126
1990 102
1991 127
1992 134
1993 130
1994 141
1995 119
1996 105
1997 106
1998 157
1999 166
2000 175
2001 186
2002 174
2003 176
2004 189
2005 178
2006 169
2007 184
2008 202
2009 182
2010 187
2011 215
2012 247
2013 260
2014 260
2015 255
2016 268
2017 288
2018 307
2019 298
2020 342
2021 372
2022 363
2023 354
2024 362
2025 142

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,091 results

Results by year

Filters applied: . Clear all
Page 1
DOCK2 is involved in the host genetics and biology of severe COVID-19.
Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, Tanaka H, Azekawa S, Mikami Y, Lee H, Hasegawa T, Okudela K, Okuzaki D, Motooka D, Kanai M, Naito T, Yamamoto K, Wang QS, Saiki R, Ishihara R, Matsubara Y, Hamamoto J, Hayashi H, Yoshimura Y, Tachikawa N, Yanagita E, Hyugaji T, Shimizu E, Katayama K, Kato Y, Morita T, Takahashi K, Harada N, Naito T, Hiki M, Matsushita Y, Takagi H, Aoki R, Nakamura A, Harada S, Sasano H, Kabata H, Masaki K, Kamata H, Ikemura S, Chubachi S, Okamori S, Terai H, Morita A, Asakura T, Sasaki J, Morisaki H, Uwamino Y, Nanki K, Uchida S, Uno S, Nishimura T, Ishiguro T, Isono T, Shibata S, Matsui Y, Hosoda C, Takano K, Nishida T, Kobayashi Y, Takaku Y, Takayanagi N, Ueda S, Tada A, Miyawaki M, Yamamoto M, Yoshida E, Hayashi R, Nagasaka T, Arai S, Kaneko Y, Sasaki K, Tagaya E, Kawana M, Arimura K, Takahashi K, Anzai T, Ito S, Endo A, Uchimura Y, Miyazaki Y, Honda T, Tateishi T, Tohda S, Ichimura N, Sonobe K, Sassa CT, Nakajima J, Nakano Y, Nakajima Y, Anan R, Arai R, Kurihara Y, Harada Y, Nishio K, Ueda T, Azuma M, Saito R, Sado T, Miyazaki Y, Sato R, Haruta Y, Nagasaki T, Yasui Y, Hasegawa Y, Mutoh Y, Kimura T, Sato T, Takei R, Hagimoto S,… See abstract for full author list ➔ Namkoong H, et al. Among authors: yoshida s. Nature. 2022 Sep;609(7928):754-760. doi: 10.1038/s41586-022-05163-5. Epub 2022 Aug 8. Nature. 2022. PMID: 35940203 Free PMC article.
Reply.
Yoshida S, Koshima I, Imai H, Sasaki A, Nagamatsu S, Yokota K. Yoshida S, et al. J Vasc Surg Cases Innov Tech. 2021 May 3;7(3):403. doi: 10.1016/j.jvscit.2021.04.007. eCollection 2021 Sep. J Vasc Surg Cases Innov Tech. 2021. PMID: 34278069 Free PMC article. No abstract available.
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N. Nakaoka Y, et al. Among authors: yoshida s. Ann Rheum Dis. 2018 Mar;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878. Epub 2017 Nov 30. Ann Rheum Dis. 2018. PMID: 29191819 Free PMC article. Clinical Trial.
Periostin in vitreoretinal diseases.
Yoshida S, Nakama T, Ishikawa K, Nakao S, Sonoda KH, Ishibashi T. Yoshida S, et al. Cell Mol Life Sci. 2017 Dec;74(23):4329-4337. doi: 10.1007/s00018-017-2651-5. Epub 2017 Sep 14. Cell Mol Life Sci. 2017. PMID: 28913545 Free PMC article. Review.
Periostin in Eye Diseases.
Yoshida S, Umeno Y, Haruta M. Yoshida S, et al. Adv Exp Med Biol. 2019;1132:113-124. doi: 10.1007/978-981-13-6657-4_12. Adv Exp Med Biol. 2019. PMID: 31037630 Review.
[Tumor Immunogenicity and Immune Checkpoint Inhibitors].
Nakajima M, Tsunedomi R, Shindo Y, Tokumitsu Y, Matsui H, Watanabe Y, Tomochika S, Yoshida S, Iida M, Suzuki N, Takeda S, Ioka T, Hazama S, Nagano H. Nakajima M, et al. Among authors: yoshida s. Gan To Kagaku Ryoho. 2022 Sep;49(9):922-927. Gan To Kagaku Ryoho. 2022. PMID: 36156006 Review. Japanese.
Role of interferons in diabetic retinopathy.
Li BY, Tan W, Zou JL, He Y, Yoshida S, Jiang B, Zhou YD. Li BY, et al. Among authors: yoshida s. World J Diabetes. 2021 Jul 15;12(7):939-953. doi: 10.4239/wjd.v12.i7.939. World J Diabetes. 2021. PMID: 34326947 Free PMC article. Review.
Macropinocytosis, mTORC1 and cellular growth control.
Yoshida S, Pacitto R, Inoki K, Swanson J. Yoshida S, et al. Cell Mol Life Sci. 2018 Apr;75(7):1227-1239. doi: 10.1007/s00018-017-2710-y. Epub 2017 Nov 8. Cell Mol Life Sci. 2018. PMID: 29119228 Free PMC article. Review.
8,091 results